Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 55 Recurrence 10 Neoplasms, Plasma Cell 3 Smoldering Multiple Myeloma 2 Hematologic Neoplasms 2 Primary Myelofibrosis 1 Polycythemia Vera 1 Neoplasms 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 444 Rituximab 401 Etoposide 224 Vincristine 215 Doxorubicin 201 Filgrastim 200 Prednisone 176 Cytarabine 159 Radiotherapy 152 fludarabine phosphate 147 Methotrexate 137 Peripheral Blood Stem Cell Transplantation 129 Melphalan 127 fludarabine 115 Busulfan 99 Dexamethasone 93 Tacrolimus 75 Carmustine 74 Granulocyte Colony-Stimulating Factor 73 Mycophenolic Acid 71 Gemcitabine 66 Bortezomib 65 Antilymphocyte Serum 65 Whole-Body Irradiation 62 Cyclosporine 62 Bendamustine Hydrochloride 62 Lenalidomide 60 Ifosfamide 58 sargramostim 51 Methylprednisolone 49

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphoma × elotuzumab × Clear all

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡